StockNews.AI
HIMS
StockNews.AI
27 days

HIMS & HERS HEALTH INC. (NYSE: HIMS) CLASS ACTION NOTICE: Berger Montague Encourages Investors With Substantial Losses to Contact the Firm By August 25, 2025

1. Securities fraud investigation launched against Hims & Hers Health Inc. 2. Investors may have been misled about regulatory compliance. 3. Stock dropped over 34% after Novo Nordisk partnership ended. 4. Class action lawsuit filed for failure to disclose drug offering risks. 5. Investors from April to June 2025 can seek lead plaintiff status.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock's more than 34% drop indicates severe investor concern and vulnerability, akin to previous scandals where stocks struggled long-term post-lawsuit, like Valeant Pharmaceuticals.

How important is it?

The investigation and class action suit directly threaten Hims & Hers, significantly impacting stock performance and investor sentiment.

Why Long Term?

Legal battles and potential penalties can damage brand perception and investor trust for extended periods.

Related Companies

NVOVRTXHIMX
, /PRNewswire/ -- Berger Montague announces a securities fraud investigation into Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) concerning potential violations of the Securities Exchange Act of 1934. The inquiry focuses on whether investors were misled about the Company's regulatory compliance and business operations. Following Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, the Company's stock dropped more than 34%. A class action lawsuit has been filed, alleging that Hims & Hers failed to disclose risks tied to its compounded drug offerings. If you acquired Hims & Hers stock during the Class Period of April 29, 2025 through June 22, 2025, you may seek lead plaintiff status in the case. The lead plaintiff represents other harmed investors in the litigation. If you are a Hims & Hers investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News